ArticleCancer reports (Hoboken, N.J.)2024
Tissue Cadherin 17 (CDH17): An Important Prognostic Determinant of Colorectal Cancer Using Digital Image Analysis.
Article in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Novel ADC and γδ T cell engager targeting CDH17 for the therapy of gastrointestinal cancers.Antibody therapeutics · 2026Article
- Cadherin 17 and digestive cancers: from diagnostic to therapeutic opportunities.Journal of experimental & clinical cancer research : CR · 2026Review
- CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors.Frontiers in immunology · 2026Review
- Evidence for the Prognostic Value of CDH17 Expression in Colorectal Carcinoma.International journal of molecular sciences · 2025Article
- Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a commonly diagnosed malignancy with significant mortality rates worldwide. The identification of robust prognostic biomarkers for prediction of survival outcomes and recurrence can aid disease management and improve patients' quality of living.
aimThis study aimed to investigate the prognostic value of cadherin 17 (CDH17) tissue expression in CRC patients by utilizing a standardized automated immunohistochemistry (IHC) platform integrated with a digitalized scoring system. METHODS AND
resultsIHC was conducted to assess CDH17 expression on tumor tissues obtained from 150 retrospective CRC cases. A computer-assisted imaging analysis was performed to quantify CDH17 tissue expression using an IHC scoring algorithm known as the Membrane (M) Score. The relationship between CDH17 M Score and clinicopathological factors such as TNM staging, distant metastasis, and recurrence status was analyzed. The prognostic value of CDH17 M Score was determined by Kaplan-Meier curves and Cox regression analysis for overall survival (OS) and recurrence-free survival (RFS). Comparison of M Score and pathologist visual scoring was made to assess the validity of software-derived IHC scoring. CDH17 expression, as measured by M Score, was found to be significantly increased in tumor tissues compared to adjacent normal tissues, and its expression is associated with advanced staging and distant metastasis (normal vs. tumor, p = 0.0011; Stages IV vs. I-III, p < 0.0162; with vs. without metastasis, p = 0.0026; Mann-Whitney U test). Prognostic analysis revealed that high CDH17 M Score was associated with poor OS and RFS (OS, p = 0.0118; RFS, p = 0.0021; log-rank test). Furthermore, multivariate Cox regression analysis identified that CDH17 M Score was an independent prognostic predictor for OS (HR = 2.296, 95% CI = 1.154-4.968, p = 0.0240) and RFS (HR = 2.489, 95% CI = 1.062-6.494, p = 0.0447).
conclusionIncreased CDH17 M Score was associated with advanced tumor staging and poor survival outcomes using an automated IHC system integrated with a digital image analysis software, highlighting CDH17 could serve as an independent prognostic marker for CRC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.